This pharmaceutical province, the first quarter of drug sales plummeted!

[Dynamic Networkpharmaceutical industry] some time ago, Henan Province Public Resource Exchange Center announced the "publicity about the first quarter of 2020, the province drugs online transactions," which publicized the total amount of orders for the first quarter of Henan Province , the total amount of the distribution, the total amount of storage, procurement varieties number YoY changesprovince this medicine, pharmaceutical sales in the first quarter plummeted!From the data, Henan Province, a quarter of drugs online trading year on year, the chain decreased substantiallyAmong them, the amount of orders decreased 23.16% year on year, down 17.61 percent year on year distribution, warehousing fell 14.07% year on yearIn addition, the data show, 2020Q1, there are 86 medical institutions did not carry out online purchases through the provincial pharmaceutical procurement platformSome manufacturers supply a lower rate, such as Zhuhai Anson Phoenix Pharmaceutical Co., Ltdand other 77 manufacturers supply less than 50%in fact, has been Henan Province is the most populated province, is also the province medicationTherefore, the drug trade in Henan Province generally reflect the national pharmaceutical market in the first quarter of 2020 transactionsThe moment the first quarter of this year, due to special reasons, hospital patient treatment blocked, blocked the flow of drugs, etc., resulting in all areas of the pharmaceutical industry has been seriously affected, but this effect is also reflected in the online trading of drugs in some provincesBut in fact, a quarter of pharmaceutical sales decline, in fact, only one of the epitome of the development of the pharmaceutical industryAnother data show that the first quarter of 2020, 238 pharmaceutical companies total operating income decreased by 2.6%, of the total net profit fell 6.1% owned by the parentHowever, in this process, different segments of showed a different responseRevenue fellwhere medical services, other biological drug other than blood products and vaccines, injection medicine, oral medicine and other more seriousSuch as the Columbine medicine, in the first quarter of this year, the company expects profit of 00,000 to 33,568,800 yuan, down 100-90% a year earlier Among the factors affecting changes in performance, the primary is affected by the epidemic, medical institutions, non-epidemic departments did not work properly carry out treatment, resulting in the company infusion product sales fell sharply from a year earlier as opposed to innovation chain drug industry, medical equipment, medical Internet has shown a growth in revenues and profits In recent years, innovative drugs such as deep plowing of Henry in April 27 released the 2020 first quarter report, the reporting period, the company achieved revenues of 5.527 billion yuan, an increase of 11.28%; attributable to shareholders of listed companies net profit of 13.15 billion, an increase of 10.3% Hengrui Medicine, said the gradual harvesting innovations, to play a role in driving growth for the company there April 28, the leading medical equipment Mindray Medical also released 2020 first quarter results report The report shows that: the company achieved operating income of 4.741 billion yuan, an increase of 21.39%; net profit of 1.313 billion yuan to achieve his maternal, an increase of 30.58%; net cash flow from operating interactions generated 14.20 billion yuan, up 204.34 percent Overall, the first quarter of 2020, a number of pharmaceutical companies over the years to be apparent by efforts to expand the high-end market, continue to increase investment in research, technology and other products to optimize the effectiveness of its mid-February the company has achieved basic resumed production complex, faster to get rid of the influence But most businesses in the first quarter and even in the second quarter production and sales or affected But in the long run, as the medical needs of rigid demand, prospects are still generally optimistic about In the future, the related businesses also need to continue the in-compliance under the premise of hard work, maintain a high R & D investment, optimize product mix, develop international and domestic markets, in order to better withstand market risks, seize opportunities.